Skip to main content

Ductal Carcinoma in Situ clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for
  • Xoft® Axxent® eBx® IORT System®

    Sorry, in progress, not accepting new patients

    The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. Hypothesis: IORT using the Xoft Axxent eBx System is no worse (non-inferior) than whole breast irradiation (WBI) when used as stand-alone radiation treatment in breast conserving therapy in women with early stage breast cancer.

    Los Angeles, California and other locations

Our lead scientists for Ductal Carcinoma in Situ research studies include .

Last updated: